Cargando…

Lipids as Targets for Renal Cell Carcinoma Therapy

Kidney cancer is among the top ten most common cancers to date. Within the kidney, renal cell carcinoma (RCC) is the most common solid lesion occurring. While various risk factors are suspected, including unhealthy lifestyle, age, and ethnicity, genetic mutations seem to be a key risk factor. In par...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stepanovska Tanturovska, Bisera, Manaila, Roxana, Fabbro, Doriano, Huwiler, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963825/ https://www.ncbi.nlm.nih.gov/pubmed/36834678 http://dx.doi.org/10.3390/ijms24043272

Ejemplares similares

Loss of S1P Lyase Expression in Human Podocytes Causes a Reduction in Nephrin Expression That Involves PKCδ Activation
por: Imeri, Faik, et al.
Publicado: (2023)

Sphk1 and Sphk2 Differentially Regulate Erythropoietin Synthesis in Mouse Renal Interstitial Fibroblast-like Cells
por: Hafizi, Redona, et al.
Publicado: (2022)

ST-2191, an Anellated Bismorpholino Derivative of Oxy-Fingolimod, Shows Selective S1P(1) Agonist and Functional Antagonist Potency In Vitro and In Vivo
por: Stepanovska Tanturovska, Bisera, et al.
Publicado: (2021)

Targeting Sphingosine Kinase 1 in Carcinoma Cells Decreases Proliferation and Survival by Compromising PKC Activity and Cytokinesis
por: Kotelevets, Nataliya, et al.
Publicado: (2012)

Correction: Targeting Sphingosine Kinase 1 in Carcinoma Cells Decreases Proliferation and Survival by Compromising PKC Activity and Cytokinesis
por: Kotelevets, Nataliya, et al.
Publicado: (2013)

Downregulation of S1P Lyase Improves Barrier Function in Human Cerebral Microvascular Endothelial Cells Following an Inflammatory Challenge
por: Stepanovska, Bisera, et al.
Publicado: (2020)

Downregulation of the S1P Transporter Spinster Homology Protein 2 (Spns2) Exerts an Anti-Fibrotic and Anti-Inflammatory Effect in Human Renal Proximal Tubular Epithelial Cells
por: Blanchard, Olivier, et al.
Publicado: (2018)

Morpholino Analogues of Fingolimod as Novel and Selective S1P(1) Ligands with In Vivo Efficacy in a Mouse Model of Experimental Antigen-Induced Encephalomyelitis
por: Stepanovska, Bisera, et al.
Publicado: (2020)

PI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic Diseases
por: Hillmann, Petra, et al.
Publicado: (2019)

Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma
por: Sepe, Pierangela, et al.
Publicado: (2020)

Phosphorylation, Signaling, and Cancer: Targets and Targeting
por: Marmiroli, Sandra, et al.
Publicado: (2015)

Therapeutic Targeting of Autophagy for Renal Cell Carcinoma Therapy
por: Jones, Trace M., et al.
Publicado: (2020)

Targeted therapy for renal cell carcinoma: The next lap
por: Kanesvaran, Ravindran, et al.
Publicado: (2014)

The Role of Targeted Therapy in Metastatic Renal Cell Carcinoma
por: Unnithan, Jaya, et al.
Publicado: (2007)

Biomarkers in renal cell carcinoma and their targeted therapies: a review
por: Gupta, Shruti, et al.
Publicado: (2023)

Targeted therapies in the management of renal cell carcinoma: role of bevacizumab
por: Escudier, Bernard, et al.
Publicado: (2008)

Renal Lipid Metabolism Abnormalities in Obesity and Clear Cell Renal Cell Carcinoma
por: Bobulescu, Ion Alexandru, et al.
Publicado: (2021)

An Overview of Systemic Targeted Therapy in Renal Cell Carcinoma, with a Focus on Metastatic Renal Cell Carcinoma and Brain Metastases
por: Semenescu, Liliana Eleonora, et al.
Publicado: (2023)

Systemic adjuvant therapies in renal cell carcinoma
por: Buti, Sebastiano, et al.
Publicado: (2012)

Recent Advances in the Management of Clear Cell Renal Cell Carcinoma: Novel Biomarkers and Targeted Therapies
por: Schiavoni, Valentina, et al.
Publicado: (2023)

Current Status of Targeted Therapy for Advanced Renal Cell Carcinoma
por: Cho, In-Chang, et al.
Publicado: (2012)

Progress of Molecular Targeted Therapies for Advanced Renal Cell Carcinoma
por: Conti, Alessandro, et al.
Publicado: (2013)

Targeted therapies for renal cell carcinoma in Chinese patients: focus on everolimus
por: Tan, Xiaojie, et al.
Publicado: (2015)

Cell death-related molecules and biomarkers for renal cell carcinoma targeted therapy
por: Lai, Yongchang, et al.
Publicado: (2019)

Lipid metabolism of hepatocellular carcinoma impacts targeted therapy and immunotherapy
por: Feng, Xiao-Chen, et al.
Publicado: (2023)

Targeted Therapy for Metastatic Renal Carcinoma: an Update
por: da Silva, Rodrigo Donalisio, et al.
Publicado: (2014)

Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma
por: Clark, Peter E
Publicado: (2010)

Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function
por: Mielczarek, Łukasz, et al.
Publicado: (2021)

Renal Preservation Therapy for Renal Cell Carcinoma
por: Chiu, Yichun, et al.
Publicado: (2012)

Targeted therapy for metastatic renal cell carcinoma
por: Patel, P H, et al.
Publicado: (2006)

Lipid-Based Nanocarriers in Renal RNA Therapy
por: Su, Chi-Ting, et al.
Publicado: (2022)

Natural and Natural-Based Polymers: Recent Developments in Management of Emerging Pollutants
por: Fierascu, Radu Claudiu, et al.
Publicado: (2023)

Antigenic targets in clear cell renal cell carcinoma
por: Schindler, Nicholas R., et al.
Publicado: (2023)

Emerging Targets in Clear Cell Renal Cell Carcinoma
por: Chen, Yu-Wei, et al.
Publicado: (2022)

Renal Carcinoma and Angiogenesis: Therapeutic Target and Biomarkers of Response in Current Therapies
por: Guillaume, Zoé, et al.
Publicado: (2022)

Sunitinib and other targeted therapies for renal cell carcinoma
por: Powles, T, et al.
Publicado: (2011)

A Holistic Perspective: Exosomes Shuttle between Nerves and Immune Cells in the Tumor Microenvironment
por: Dragomir, Mihnea P., et al.
Publicado: (2020)

Bone Metabolism Effects of Medical Therapy in Advanced Renal Cell Carcinoma
por: Paragliola, Rosa Maria, et al.
Publicado: (2023)

Evolving targets for lipid-modifying therapy
por: Do, Rose Q, et al.
Publicado: (2014)

Targeted Strategy in Lipid-Lowering Therapy
por: Dayar, Ezgi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_llvjqiaokj3vjfkicemibphc3p